MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation

EMBO Journal

Volumn 22, Issue 23, 2003, Pages 6365-6377

  Jin, Yetao ^a   Lee, Hunjoo ^a   Zeng, Shelya X ^a   Dai, Mu Shui ^a   Lu, Hua ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

MDM2; p21 waf1 cip1; Proteasome; Stability; Ubiquitin

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; LACTACYSTIN; LYSINE; MESSENGER RNA; MUTANT PROTEIN; PROTEASOME; PROTEIN MDM2; PROTEIN P19; PROTEIN P19 ARF; PROTEIN P21; PROTEIN P21 WAF1 CIP1; PROTEIN P53; UBIQUITIN; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYSTEINE PROTEINASE; ENZYME INHIBITOR; MDM2 PROTEIN, HUMAN; MDM2 PROTEIN, MOUSE; MULTIENZYME COMPLEX; NUCLEAR PROTEIN; ONCOPROTEIN; RECOMBINANT PROTEIN; SMALL INTERFERING RNA;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; HALF LIFE TIME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; WILD TYPE; ADENOCARCINOMA; ANIMAL; CELL CULTURE; CELL DIVISION; CELL LINE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; KINETICS; MALE; METABOLISM; MOUSE; MOUSE MUTANT; TESTIS TUMOR;

ADENOCARCINOMA; ANIMALS; CELL DIVISION; CELL LINE; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; KINETICS; MALE; MICE; MICE, KNOCKOUT; MULTIENZYME COMPLEXES; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECOMBINANT PROTEINS; RNA, SMALL INTERFERING; TESTICULAR NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 0346243936     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/cdg600     Document Type: Article

References (54)

1. Appella, E. and Anderson, C.W. (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem., 268, 2764-2772.
2. Barak, Y., Juven, T., Haffner, R. and Oren, M. (1993) mdm2 expression is induced by wild type p53 activity. EMBO J., 12, 461-468.
3. Blagosklonny, M.V., Wu, G.S., Omura, S. and el-Deiry, W.S. (1996) Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun., 227, 564-569.
4. G2 arrest after DNA damage. Science, 282, 1497-1501.
5. Calabro, V., Mansueto, G., Parisi, T., Vivo, M., Calogero, R.A. and La Mantia, G. (2002) The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J. Biol. Chem., 277, 2674-2681.
6. Canman, C.E., Lim, D.S., Cimprich, K.A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M.B. and Siliciano, J.D. (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science, 281, 1677-1679.
7. Chen, J., Marechal, V. and Levine, A.J. (1993) Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol., 13, 4107-4114.
8. Chen, J., Jackson, P.K., Kirschner, M.W. and Dutta, A. (1995) Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature, 374, 386-388.
9. Clark, P.A., Llanos, S. and Peters, G. (2002) Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2. Oncogene, 21, 4498-4507.
10. Crook, T., Marston, N.J., Sara, E.A. and Vousden, K.H. (1994) Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell, 79, 817-827.
11. Datto, M.B., Li, Y., Panus, J.F., Howe, D.J., Xiong, Y. and Wang, X.F. (1995) Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl Acad. Sci. USA, 92, 5545-5549.
12. David, D.C., Layfield, R., Serpell, L., Narain, Y., Goedert, M. and Spillantini, M.G. (2002) Proteasomal degradation of tau protein. J. Neurochem., 83, 176-185.
13. deStanchina, E. et al. (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev., 12, 2434-2442
14. el-Deiry, W.S. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
15. Fang, S., Jensen, J.P., Ludwig, R.L., Vousden, K.H. and Weissman, A.M. (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem., 275, 8945-8951.
16. Freedman, D.A. and Levine, A.J. (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell Biol., 18, 7288-7293.
17. Fuchs, S.Y., Adler, V., Buschmann, T., Wu, X. and Ronai, Z. (1998) Mdm2 association with p53 targets its ubiquitination. Oncogene, 17, 2543-2547.
18. Fukuchi, K., Maruyama, H., Takagi, Y. and Gomi, K. (1999) Direct proteasome inhibition by clasto-lactacystin β-lactone permits the detection of ubiquitinated p21(waf1) in ML-1 cells. Biochim. Biophys Acta, 1451, 206-210.
19. Giaccia, A.J. and Kastan, M.B. (1998) The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev., 12, 2973-2983.
20. Gu, W. and Roeder, R.G. (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 90, 595-606.
21. 1 cyclin-dependent kinases. Cell, 75, 805-816.
22. Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-299.
23. Honda, R. and Yasuda, H. (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J., 18, 22-27.
24. Honda, R., Tanaka, H. and Yasuda, H. (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett., 420, 25-27.
25. Hoyt, M.A., Zhang, M. and Coffino, P. (2003) Ubiquitin-independent mechanisms of mouse ornithine decarboxylase degradation are conserved between mammalian and fungal cells. J. Biol. Chem., 278, 12135-12143
26. Kamijo, T., Weber, J.D., Zambetti, G., Zindy, F., Roussel, M.F. and Sherr, C.J. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl Acad. Sci. USA, 95, 8292-8297.
27. Keller, D.M. et al. (2001) A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16 and SSRP1. Mol. Cell, 7, 283-292.
28. Kubbutat, M.H., Jones, S.N. and Vousden, K.H. (1997) Regulation of p53 stability by Mdm2. Nature, 387, 299-303.
29. Llanos, S., Clark, P.A., Rowe, J. and Peters, G. (2001) Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nature Cell Biol., 3, 445-452.
30. Maki, C.G. and Howley, P.M. (1997) Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell Biol., 17, 355-363.
31. Michael, D. and Oren, M. (2003) The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol., 13, 49-58.
32. Migliorini, D., Denchi, E.L., Danovi, D., Jochemsen, A., Capillo, M., Gobbi, A., Helin, K., Pelicci, P.G. and Marine, J.C. (2002) Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell Biol., 22, 5527-5538.
33. Momand, J., Zambetti, G.P., Olson, D.C., George, D. and Levine, A.J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
34. Nakanishi, Y. et al. (2000) Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21. Am. J. Respir. Cell Mol. Biol., 22, 747-754.
35. Orlowski, M. and Wilk, S. (2003) Ubiquitin-independent proteolytic functions of the proteasome. Arch. Biochem. Biophys., 415, 1-5.
36. Parant, J., Chaves-Reyes, A., Little, N.A., Yan, W., Reinke, V., Jochemsen, AG. and Lozano, G. (2001) Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a novoverlapping pathway with MDM2 to regulate p53. Nature Genet., 29, 92-95.
37. Sheaff, R.J., Singer, JD., Swanger, J., Smitherman, M., Roberts, J.M. and Clurman, B.E. (2000) Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell, 5, 403-410.
38. Shieh, S.Y., Ikeda, M., Taya, Y. and Prives, C. (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
39. Sun, P., Dong, P., Dai, K., Hannon, G.J. and Beach, D. (1998) p53-independent role of MDM2 in TGF-β1 resistance. Science, 282, 2270-2272.
40. Tao, W. and Levine, A.J. (1999) P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc. Natl Acad. Sci. USA, 96, 6937-6941.
41. Touitou, R., Richardson, J., Bose, S., Nakanishi, M., Rivett, J. and Allday, M.J. (2001) A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 α-subunit of the 20S proteasome. EMBO J., 20, 2367-2375.
42. Verma, R. and Deshaies, R.J. (2000) A proteasome howdunit: the case of the missing signal. Cell, 101, 341-344.
43. Vogelstein, B., Lane, D. and Levine, A.J. (2000) Surfing the p53 network. Nature, 408, 307-310.
44. Weber, J.D., Taylor, L.J., Roussel, M.F., Sherr, C.J. and Bar-Sagi, D. (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol., 1, 20-26.
45. Weber, J.D., Kuo, M.L., Bothner, B., DiGiammarino, E.L., Kriwacki, R.W., Roussel, M.F. and Sherr, C.J. (2000) Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol. Cell Biol., 20, 2517-2528
46. Wu, X., Bayle, J.H., Olson, D. and Levine, A.J. (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 7, 1126-1132.
47. Xiao, Z.X., Chen, J., Levine, A.J., Modjtahedi, N., Xing, J., Sellers, W.R. and Livingston, D.M. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 373, 694-698.
48. Xirodimas, D., Saville, M.K., Edling, C., Lane, D.P. and Lain, S. (2001) Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Oncogene, 20, 4972-4983.
49. Xie, Y. and Varshavsky, A. (2000) Physical association of ubiquitin ligases and the 26S proteasome. Proc. Natl Acad. Sci. USA, 97, 2497-2502.
50. Yu, Z.K., Geyer, R.K. and Maki, C.G. (2000) MDM2-dependent ubiquitination of nuclear and cytoplasmic p53. Oncogene, 19, 5892-5897.
51. Zeng, S.X., Dai, M.S., Keller, D.M. and Lu, H. (2002) SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J., 21, 5487-5497.
52. Zeng, X. et al. (1999) MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell Biol., 19, 3257-3266.
53. Zhang, Y., Xiong, Y. and Yarbrough, W.G. (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92, 725-734.
54. Zindy, F., Eischen, C.M., Randle, D.H., Kamijo, T., Cleveland, J.L., Sherr, C.J. and Roussel, M.F. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev., 12, 2424-2433.